Clinical Trial Update: Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing erlotinib plus tivantinib (ARQ 197) versus single-agent chemotherapy in locally advanced or metastatic non-small cell lung cancer; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ARQ 197 (tivantinib)
• Tarceva (erlotinib)

Snippet

Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Conditions: Metastatic Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-04-03